Objectives
- Periodic survey of the research communities’ needs
- Development of recommendations for radiologists to engage with different fields of research and innovation
- Provide strategic recommendations for the research field to the ESR Executive Council
- Leverage cooperation between research disciplines
- Provide the liaison of the ESR with the European Institute for Biomedical Imaging Research (EIBIR) and help to promote its services and activities
- Foster networking and liaising with scientific biomedical European societies
- Provide recommendations and guidelines for lung cancer screening jointly with the European Respiratory Society
- Coordinate activities related to imaging biobanks and biomarkers (see EIBALL):
- To promote the development of imaging biobanks and intelligent tools for the analysis and processing of imaging biomarkers
- To promote the standardisation, validation and benchmarking of the imaging data included in those biobanks
- To stimulate the linking and integration of existing (national and regional) image data repositories related to populations, screening /early detection and disease
- To stimulate the link between imaging biobanks and traditional biobanks through the development of standards and liaison with BBMRI-ERIC (Biobanking and BioMolecular resources Research Infrastructure)
- To explore the economical, ethical/legal issues for the management of imaging biobanks
- Coordinate activities aimed to foster research education:
- To assess the current status of and develop recommendations on how to improve education in research
- To regularly update the input of research into the ESR European Training Curriculum for Radiology
European Imaging Biomarkers Alliance - EIBALL
The activities of the former ESR Subcommittee on Imaging Biomarkers, ESR Working Group on Personalised Medicine and ESR-EORTC Working Group were merged into EIBALL.
Objectives
- Coordinate all ESR activities concerning imaging biomarkers
- Prepare an inventory of all activities and projects in the field of imaging biomarkers where the ESR is involved
- Serve as a tool box that provides information about current projects, centres involved in clinical trials and educational activities
- Define possible imaging biomarkers in different human body regions; oncologic as well as non-oncologic
- Establish a functional biomarker profile that is current and relevant through the development of an online inventory of biomarkers
- Enable and encourage the clinical use of biomarkers by setting standards for data acquisition and image processing
- Closely collaborate with EIBIR to maintain an updated list of European centres of excellence (core institutions) for the implementation and clinical validation of imaging biomarkers
- Closely collaborate with the EORTC (European Organisation for Research and Treatment of Cancer) and its Imaging Group with regard to the inclusion of radiologists in multicentre trials and the development of a biomarker inventory
- Closely collaborate with QIBA (technical validation synergies) to avoid duplication of development and EORTC (biological validation) to coordinate strategies, find complementarity, and benefit from synergies
ESOR/EIBALL Course on Research in Diagnostic Radiology - How to Build the Perfect Study
16th November, Vienna, Austria
As part of it's two-year roadmap, the EIBALL Subcommittee is committed to promoting education on appropriate use of functional imaging biomarkers and their interpretation. This workshop will help participants learn how to develop a research project to discover and validate an imaging parameter (e.g. radiological sign, perfusion, ADC, diagnostic algorithm, radiomics signature).
EIBALL Mission Statement
Click below to view the EIBALL mission statement and 2-year roadmap.
EIBALL collaborations
EIBALL collaborates with the Quantitative Imaging Biomarkers Alliance (QIBA)
QIBA is an important part of the Radiological Society of North America’s (RSNA) commitment to transforming radiology from a qualitative to a more quantitative science and to the improved patient care resulting from accelerated development and dissemination of new pharmacologic, biologic and interventional diagnosis and treatment approaches.